Entdoc, you never know. Maybe Genentech would be interested in a partnership for imaging? The paper does have this at the end of the discussion section. ... the presented PS-targeting antibody (89Zr-PGN635) has a potential to become a broadly applicable imaging agent independent on cancer type since PS is a generic component of the plasma membrane.